IMUX vs. AGLE, VERV, ERAS, BMEA, LXRX, NGNE, TBPH, TERN, SLRN, and ESPR
Should you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Aeglea BioTherapeutics (AGLE), Verve Therapeutics (VERV), Erasca (ERAS), Biomea Fusion (BMEA), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Acelyrin (SLRN), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical preparations" industry.
Aeglea BioTherapeutics (NASDAQ:AGLE) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
51.8% of Immunic shares are held by institutional investors. 6.6% of Aeglea BioTherapeutics shares are held by insiders. Comparatively, 3.0% of Immunic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Aeglea BioTherapeutics has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, Immunic has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.
Aeglea BioTherapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Immunic has a net margin of 0.00% compared to Immunic's net margin of -22,195.36%. Immunic's return on equity of -132.05% beat Aeglea BioTherapeutics' return on equity.
Aeglea BioTherapeutics received 160 more outperform votes than Immunic when rated by MarketBeat users. However, 65.73% of users gave Immunic an outperform vote while only 56.70% of users gave Aeglea BioTherapeutics an outperform vote.
In the previous week, Immunic had 2 more articles in the media than Aeglea BioTherapeutics. MarketBeat recorded 2 mentions for Immunic and 0 mentions for Aeglea BioTherapeutics. Aeglea BioTherapeutics' average media sentiment score of 0.29 beat Immunic's score of 0.00 indicating that Immunic is being referred to more favorably in the news media.
Aeglea BioTherapeutics presently has a consensus price target of $17.50, suggesting a potential upside of ∞. Immunic has a consensus price target of $8.50, suggesting a potential upside of 585.48%. Given Immunic's higher probable upside, equities analysts plainly believe Aeglea BioTherapeutics is more favorable than Immunic.
Summary
Immunic beats Aeglea BioTherapeutics on 9 of the 17 factors compared between the two stocks.
Get Immunic News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
